346 people, no control group, and a signal worth taking seriously
THE DISPATCH
Oregon’s licensed psilocybin service centers have operated since 2023, but until this month, no peer-reviewed study had tracked what happens to the people who use them beyond basic safety counts. On August 19, 2026, JAMA Network Open published the first such study: 346 people surveyed at baseline and again at one week, one month, and three months after a supervised session.¹ The topline finding is genuinely encouraging. It is also a naturalistic, self-reported, uncontrolled dataset, and the difference between those two facts is exactly what a clinician needs to be precise about with a patient who asks.
In this issue:
→ What the first published outcomes study on Oregon’s psilocybin program actually measured, and what it can’t tell you
→ How its safety data compares to what controlled trials have already established
→ Compass’s own PTSD-specific trial, and a Massachusetts bill that would open a very different kind of access model
THE SCIENCE
Researchers at Oregon Health & Science University, led by P. Todd Korthuis, MD, MPH, with senior co-author Adrianne Wilson-Poe, PhD, recruited 346 adults who used one of 24 licensed Oregon service centers between November 2024 and June 2026.¹ Participants completed standardized wellbeing and symptom measures through a web portal before their session, then again at one week, one month, and three months afterward. At one month, 92.2 percent reported benefiting from the experience, and 58.6 percent ranked it among the ten most meaningful experiences of their lives.¹ At three months, the prevalence of moderate to severe symptoms fell relative to baseline for depression (relative risk 0.40), anxiety (relative risk 0.29), and PTSD symptoms (relative risk 0.35).¹ These are longitudinal improvements following psilocybin services, not estimates of psilocybin’s treatment effect.
On safety, the numbers are specific and worth stating plainly rather than rounding up or down: at three months, 7 of 312 participants, roughly 2 percent, reported the experience as harmful, and 4 of 346 participants, all psychedelic-naive, experienced serious behavioral adverse reactions requiring medical attention. No serious medical adverse events were reported.¹ The available data suggest that serious adverse reactions in Oregon’s regulated program are uncommon, broadly reassuring, and not obviously discordant with the safety experience reported in controlled psilocybin studies, notable given that Oregon sessions happen outside a research protocol, with dosing and screening handled by licensed facilitators rather than clinical investigators.¹
Here is what this study is not. It has no control group, no comparison to people who wanted a session but didn’t get one, and no way to separate the effect of psilocybin from the effect of six hours of structured attention, an intentional setting, and the belief that something meaningful was about to happen. Everyone in the sample chose to participate, paid out of pocket, and completed voluntary follow-up surveys, which means the group very likely differs systematically from the general population in ways that push the results in a positive direction. The findings therefore may not generalize to patients encountered in routine psychiatric or neurological practice, particularly those with greater medical or psychiatric complexity. The authors are explicit about these limits in the paper itself. What the study adds is not proof of efficacy. It is the first real-world signal, published and peer-reviewed rather than reported as program statistics, that a legal, non-clinical access model isn’t producing outcomes wildly out of step with what controlled research already shows.
That distinction is the one worth carrying into a conversation with a patient who has read a headline about this study and wants to know what it means for them. A patient asking whether Oregon’s program is “as good as” a clinical trial is asking a question this study cannot answer, because it wasn’t designed to answer it. A patient asking whether the safety profile outside a research setting looks reasonable is asking a question this study speaks to directly, and reasonably well.
For the field more broadly, this is also the first time a state’s adult-access model has produced a dataset serious enough to run in a major peer-reviewed journal rather than a state agency report. That alone changes what kind of citation this program can support the next time a policymaker, insurer, or skeptical colleague asks for evidence rather than anecdote.
THE STORY
Three months after their session, participants who had screened positive for moderate to severe depression, anxiety, or PTSD symptoms at baseline reported reductions across all three measures, tracked through the same standardized instruments used at intake.¹ The researchers did not follow up on what specifically changed in each person’s life during those three months, and that is precisely the limitation worth naming honestly. The observational design cannot determine what produced these changes. Psilocybin itself, the therapeutic context, expectancy, subsequent behavioral or psychological changes, and other events occurring during the follow-up period may all have contributed. The persistence of improvement is noteworthy, but this study cannot establish causality or isolate the contribution of the drug itself. What the data supports is narrower and still useful: people who sought this out, in a legal and supervised setting, were not on average harmed, and many reported the kind of shift that patients describe wanting when they raise psilocybin with a clinician in the first place.
ON OUR RADAR
① Compass Opens a Dedicated PTSD Program
The FDA has accepted Compass Pathways’ IND for COMP202, a Phase 2b/3 trial testing synthetic psilocybin (COMP360) specifically for PTSD, with a primary endpoint on the CAPS-5 scale at week eight and an open-label extension studying retreatment.² This runs separately from Compass’s depression program and is the company’s first PTSD-dedicated trial.
② Massachusetts Moves Toward a Clinic-Based Access Model
On July 9, 2026, the Massachusetts House passed a bill 148 to 2 creating a five-year pilot allowing supervised psilocybin therapy at up to three licensed mental health clinics for depression, anxiety, PTSD, and substance use disorder.³ Unlike Oregon’s service-center model, this would embed psilocybin sessions inside licensed clinical settings with mandatory outcome tracking, a structurally different access model worth watching if the Senate and Governor Healey advance it.
③ A Third Compound Class Reaches a PTSD Milestone
Transcend Therapeutics published Phase 2 results for TSND-201 (methylone), a monoamine-releasing neuroplastogen mechanistically distinct from classic 5-HT2A psychedelics such as psilocybin, showing a statistically significant CAPS-5 improvement over placebo in patients with severe PTSD.⁴ It is not a psilocybin trial, but its published, controlled design is the kind of comparison point worth having on hand the next time someone asks how a real-world study like Oregon’s stacks up against one built with a placebo arm.
YOU ASKED
Q: “A patient told me they’re thinking about traveling to Oregon for a psilocybin session instead of waiting for a clinical trial. What should I actually tell them?”
Tell them what this month’s study does and doesn’t establish. It’s the first peer-reviewed evidence that people using Oregon’s licensed program report meaningful benefit and a safety profile that appears broadly reassuring and not obviously discordant with controlled research, which is a real, useful data point. It is not a controlled trial, has no placebo or waitlist comparison, and the people in it were self-selected and paid out of pocket, all of which make it easier for a positive result to appear than a rigorous trial would allow. The most accurate thing you can say is that supervised, legal access in Oregon appears reasonably safe based on the best data available so far, and that randomized controlled trials remain our best available method for estimating how much of the observed improvement is attributable to psilocybin itself rather than expectancy, setting, natural symptom fluctuation, and other nonspecific factors. Both facts can be true, and a patient deciding between the two deserves to hear both.
THE TAKEAWAY
This week’s takeaway: the first peer-reviewed study of Oregon’s licensed psilocybin program found high self-reported benefit and a safety profile that appears broadly reassuring and not obviously discordant with controlled trials, in a real-world, uncontrolled sample of 346 people. It’s a genuine signal, not proof, and the distinction is worth stating plainly every time this study comes up.
A question worth sitting with: how much evidentiary weight should a state’s own access program be allowed to carry once it starts publishing in the same journals as the clinical trials it was never designed to replace?
Read the study directly: JAMA Network Open: Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services
If a patient has asked you about psilocybin and you weren’t sure where to point them, this is the source. Forward it to one colleague fielding the same question.
Burton Tabaac, MD
Vascular Neurologist and Psychedelic Researcher, Rose Hill Life Sciences
Advancing the development of novel psychedelic-based therapeutics
FOOTNOTES
¹ Korthuis, P.T., Wilson-Poe, A.R., et al. “Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services.” JAMA Network Open, August 19, 2026. DOI: 10.1001/jamanetworkopen.2026.30608. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2853028 | Oregon Health & Science University. “Study finds sustained benefit for people using Oregon psilocybin services.” August 19, 2026. https://news.ohsu.edu/2026/08/19/study-finds-sustained-benefit-for-people-using-oregon-psilocybin-services
² Compass Pathways. “Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD.” January 7, 2026. https://ir.compasspathways.com/News–Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Acceptance-of-IND-Application-for-PTSD-and-Hosts-Webinar-on-PTSD-and-TRD/default.aspx
³ Marijuana Moment. “Massachusetts Lawmakers Pass Bill To Legalize Psychedelic Therapy With New Pilot Program.” July 9, 2026. https://www.marijuanamoment.net/massachusetts-lawmakers-pass-bill-to-legalize-psychedelic-therapy-with-new-pilot-program/
⁴ Transcend Therapeutics. “IMPACT-1 Study Published in JAMA Psychiatry: Results of TSND-201 (Methylone) in Patients with Severe PTSD.” February 18, 2026. https://transcendtherapeutics.com/impact-1-study-published-in-jama-psychiatry-results-of-tsnd-201-methylone-in-patients-with-severe-ptsd/
The Rose Hill Review | Rose Hill Life Sciences | psilosignal.vercel.app
